|
12 May 2019 |
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
|
|
10 May 2019 |
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
|
|
09 May 2019 |
U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
|
|
09 May 2019 |
Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
|
|
08 May 2019 |
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
|
|
08 May 2019 |
Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
|
|
08 May 2019 |
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
|
|
08 May 2019 |
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
|
|
08 May 2019 |
Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201
|
|
07 May 2019 |
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
|
|
06 May 2019 |
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
|
|
06 May 2019 |
Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)
|
|
04 May 2019 |
FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
|
|
02 May 2019 |
Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
|
|
02 May 2019 |
UCB and University of Lille anti-tau immunotherapy research highlighted in prestigious international scientific journal ‘Brain’
|
|
01 May 2019 |
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
|
|
30 Apr 2019 |
I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma
|
|
30 Apr 2019 |
European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
|
|
30 Apr 2019 |
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
|
|
29 Apr 2019 |
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
|
|
29 Apr 2019 |
FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
|
|
28 Apr 2019 |
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
|
|
28 Apr 2019 |
FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
|
|
28 Apr 2019 |
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
|
|
28 Apr 2019 |
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
|
